Endo

Charles A. Rowland, Jr. has been appointed executive vice president, chief financial officer and treasurer, Endo Pharmaceuticals Holdings, Inc. Mr. Rowland has more than 20 years of pharmaceutical industry experience, including senior-level positions at Pharmacia Corp., Novartis, Bristol-Myers Squibb and most recently as senior vice president and chief financial officer of Biovail Pharmaceuticals. In his new role, he will be responsible for all aspects of Endo’s financial and accounting operations, as well as corporate communications.

“We are delighted to welcome an executive of Charlie Rowland’s stature and abilities to Endo’s senior management team,” said Peter A. Lankau, president and chief executive officer. “He brings a successful track record that includes broad-based industry experience, keen financial and transaction acumen and an aligned strategic vision that we believe will benefit us as we enter the next phase of our growth.” Mr. Rowland replaces Endo’s former chief financial officer, Jeff Black, who retired in August.

The company has also promoted David E. Kerr to senior vice president, commercial business, to head the sales and marketing efforts for the both branded and generic businesses.